Genezen to buy uniQure’s gene therapy operations in Lexington (NASDAQ:QURE)

  • Genezen said it will acquire uniQure’s (NASDAQ:QURE) commercial gene therapy operations in Lexington.
  • Under the agreement, Genezen will enter into strategic supply agreements for uniQure’s clinical portfolio and CSL’s commercial HEMGENIX product.
  • The deal will be partly funded by additional growth equity from Ampersand Capital Partners.